Skip to content

Subarachnoid-Subarachnoid (S-S) Bypass Versus Adhesion Lysis in Spinal Arachnoiditis and Syringomyelia

Subarachnoid-Subarachnoid (S-S) Bypass Versus Adhesion Lysis in Spinal Arachnoiditis and Syringomyelia

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06375759
Enrollment
200
Registered
2024-04-19
Start date
2024-04-30
Completion date
2027-04-30
Last updated
2024-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Syringomyelia

Keywords

syringomyelia

Brief summary

To determine whether Subarachnoid-Subarachnoid (S-S) Bypass results in better patient outcomes with fewer complications and improved quality of life compared to intradural adhesion lysis in individuals with Spinal Arachnoiditis and Syringomyelia.

Detailed description

Participants with Spinal Arachnoiditis and Syringomyelia will be randomized to either have a Subarachnoid-Subarachnoid (S-S) Bypass or intradural adhesion Lysis. The participant will then return to the neurosurgeon's office at the following time points which are consistent with standard of care practice: 3-6 months, 12 and 24 months. At these visits, the clinician will complete a physical exam and the participant will report on the prognosis of symptoms and complete questionnaires. A spine MRI will be performed 3-6 months, 12 and 24 months after the decompression.

Interventions

PROCEDURESubarachnoid-Subarachnoid (S-S) Bypass

The dura was widely exposed beyond the level of trauma, and then a midline dural opening was made under an operative microscope. When dura and arachnoid were adhered because of an expansion of arachnoiditis, they had to be released with great care to place the bypass tubes. During this procedure, S-S bypass was not usually needed to performed arachnoid lysis. This exposure had to reach the normal arachnoid mater free from arachnoiditis and adhesion, with normal CSF circulation. After dissections of the normal arachnoid mater at the cephalic and caudal sites, 1 or 2 tubes made of medical grade silicone (ventricular drainage tube; internal diameter 1.5-2.0 mm, external diameter 2.5-3.3 mm) were inserted into the cephalic and caudal ends of the normal subarachnoid space. The part of the tube inserted into the subarachnoid space was approximately 2 cm long.

PROCEDUREIntradural Adhesion Lysis

Intradural spinal cord Adhesion Lysis

Sponsors

Xuanwu Hospital, Beijing
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* 1\) history of traumatic spinal cord injury or other infection; 2) evidence of progressive neurological deficit, and/or pain syndrome; 3) MRI showing a syringomyelia due to spinal trauma or other infection; and 4) minimum follow-up period of more than 1 year.

Exclusion criteria

* Chiari-malformation, myelomalacia, subarachnoid cyst, syringomyelia due to other spinal diseases (such as degenerative spinal disease)

Design outcomes

Primary

MeasureTime frameDescription
complication12 monthsReoperation,Wound infection,Aseptic meningitis,CSF fistula,Subcutaneous hydrops,Other complications

Secondary

MeasureTime frameDescription
improvement or resolution of the syrinx,3-6, 12 and 24 monthsdefined as \> 50% improvement in length, maximal cross-sectional diameter, or both.
ASIA score3-6, 12 and 24 monthsAmerican Spinal Injury Association(ASIA) Score for evaluating the spinal cord function, degree of the spinal cord function, motor1-100, sensory 1-224, higher scores mean a better outcome
Klekamp and Sammi syringomyelia scale3-6, 12 and 24 monthsfor evaluating the spinal cord function, higher scores mean a better outcome
modified Japanese Orthopaedic Association Scores (mJOA)3-6, 12 and 24 monthsMotor function, sensory, bladder function;for evaluating the spinal cord function;0-17, higher scores mean a better outcome
xuanwu syringomyelia scale3-6, 12 and 24 monthsfor evaluating the spinal cord function, for evaluating the spinal cord function;0-18, higher scores mean a worse outcome

Countries

China

Contacts

Primary Contactfengzeng jian
jianfengzeng@xwh.ccmu.edu.cn01083198899
Backup Contactyuan chenghua
yuanchenghua@ccmu.edu.cn01083198899

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026